We explore the systemic implications of GHK-Cu for skin health in our article, GHK-Cu for Systemic Acne: What the Research Really Suggests About Healing From Within
reports research grants and/or personal fees from AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline, Insulet Corp, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Medtronic, Merck & Co Inc, Population Health Research Institute, Roche Pharma, Sanofi, and Takeda
There is also some evidence that tirzepatide affects gastric emptying less aggressively than semaglutide at equivalent therapeutic levels, though direct comparison data during exercise is limited
Eli Lilly's tirzepatide has also performed well, with strong market competitiveness
Veru press release, 28 May 2025: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone Rivus Pharmaceuticals press release, 30 September 2024: Regeneron press release, 2 June 2025: Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass | Regeneron Pharmaceuticals Inc
These benign spots dont cause any symptoms and dont require treatment unless they change in shape, size, or color